Microglia research findings are an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@heneka2015]
Microglia framework described a staged activation trajectory: an initial TREM2-independent transition followed by a TREM2-dependent program associated with plaque engagement.<sup>[2]</sup> [@kerenshaul2017]
This transition is not binary. Human single-nucleus and xenograft data indicate multiple microglial subpopulations, including interferon-responsive, lipid-associated, phagocytic, and exhausted/senescent-like states.<sup>[7]</sup><sup>[8]</sup><sup>[9]</sup> These states appear region-specific and disease-stage-dependent, with cortical and hippocampal microglia diverging from white matter and deep gray nuclei microglia under sustained proteostatic stress. [@sims2017]
Human genetics strongly supports a mechanistic role for microglia in Alzheimer's Disease. Large-scale association studies identified coding risk variants in innate immune genes, including TREM2, and highlighted immune signaling modules as major heritable components of disease risk.<sup>[3]</sup><sup>[5]</sup> Functionally, TREM2 signaling influences microglial metabolism, chemotaxis around plaques, and phagocytic barrier formation.<sup>[10]</sup> [@shi2018]
Microglia research findings are an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@heneka2015]
Microglia framework described a staged activation trajectory: an initial TREM2-independent transition followed by a TREM2-dependent program associated with plaque engagement.<sup>[2]</sup> [@kerenshaul2017]
This transition is not binary. Human single-nucleus and xenograft data indicate multiple microglial subpopulations, including interferon-responsive, lipid-associated, phagocytic, and exhausted/senescent-like states.<sup>[7]</sup><sup>[8]</sup><sup>[9]</sup> These states appear region-specific and disease-stage-dependent, with cortical and hippocampal microglia diverging from white matter and deep gray nuclei microglia under sustained proteostatic stress. [@sims2017]
Human genetics strongly supports a mechanistic role for microglia in Alzheimer's Disease. Large-scale association studies identified coding risk variants in innate immune genes, including TREM2, and highlighted immune signaling modules as major heritable components of disease risk.<sup>[3]</sup><sup>[5]</sup> Functionally, TREM2 signaling influences microglial metabolism, chemotaxis around plaques, and phagocytic barrier formation.<sup>[10]</sup> [@shi2018]
Recent work further links TYROBP dosage and TREM2-adaptor signaling to Alzheimer's susceptibility and immune dysfunction, refining the receptor-adaptor axis as a therapeutic target.<sup>[11]</sup> Inference from these data suggests that patient-specific microglial genotypes may alter treatment response for anti-inflammatory and anti-amyloid interventions. [@zhou2021]
Microglia can limit diffuse amyloid toxicity by clustering around plaques and promoting compaction, but sustained exposure to aggregated proteins and lipid debris drives metabolic strain and dysfunctional activation.<sup>[2]</sup><sup>[10]</sup> Studies of human Alzheimer's tissue and SEA-AD datasets report microglial signatures enriched for cholesterol dysregulation and senescence-like programs, supporting the view that metabolic failure is a key late-stage amplifier of injury.<sup>[12]</sup> [@leng2021]
A major mechanism linking inflammation to cognitive decline is Complement-Mediated Synapse Loss. Activated microglia can remove synapses tagged by complement components, particularly in vulnerable cortical circuits.<sup>[13]</sup><sup>[14]</sup> Experimental studies indicate that TREM2 signaling can modulate this axis by restraining excessive complement-driven pruning in neurodegenerative contexts.<sup>[14]</sup> [@krasemann2017]
The NLRP3 Inflammasome and upstream innate immune signaling pathways promote IL-1 family cytokine responses, glial cross-activation, and feed-forward tissue stress.<sup>[1]</sup><sup>[6]</sup> While acute responses may support host defense and debris clearance, prolonged activation can impair plasticity and increase neuronal vulnerability. [@vidatic2024]
Microglial activation contributes to Tau pathology propagation via cytokine signaling, altered phagocytic handling of extracellular tau species, and inflammatory niche formation.<sup>[15]</sup> In mixed pathologies, convergent microglial responses may also interact with alpha-Synuclein and vascular injury signals, complicating disease trajectories and biomarker interpretation. [@geirsdottir2024]
Fluid and imaging biomarkers increasingly capture microglial activity in vivo. CSF and plasma inflammatory panels, soluble TREM2 trajectories, and multi-analyte signatures are being evaluated alongside amyloid and tau markers to stage immune activity and treatment response.<sup>[16]</sup> The translational challenge is specificity: many inflammatory markers reflect broad neuroimmune activation rather than Alzheimer's-specific biology. [@xie2024]
Single-cell atlases and spatial transcriptomics are narrowing this gap by defining state-specific marker combinations that may separate protective plaque-associated microglia from harmful senescent or complement-hyperactive states.<sup>[7]</sup><sup>[12]</sup> [@singleton2025]
Therapeutic approaches targeting microglia include: [@tondo2024]
Current evidence supports stage-aware intervention: early disease may benefit from preserving adaptive microglial functions, whereas later disease may require suppressing maladaptive inflammatory states while maintaining essential homeostatic surveillance. [@wu2023]
Human single-cell and spatial transcriptomics studies in 2025-2026 have substantially advanced our understanding of microglial heterogeneity in Alzheimer's disease. [@schartz2023]
Recent research has deepened our understanding of TREM2 function. The TREM2-T96K gain-of-function mutation has been shown to increase Alzheimer's disease risk by impairing microglial function, highlighting the delicate balance of TREM2 signaling.<sup>[17]</sup> Studies on TREM2 expression enhancement demonstrate that activating microglia can modestly mitigate tau pathology and neurodegeneration, providing a potential therapeutic avenue.<sup>[18]</sup> [@chen2023]
The APOE Christchurch variant presents an interesting case of opposing effects: it enhances disease-associated microglial (DAM) responses to amyloid plaques but suppresses responses to tau pathology, suggesting region-specific modulation may be needed.<sup>[19]</sup> [@ferri2024]
Spatial transcriptomics studies of human Alzheimer's brains have uncovered distinct plaque-glia niches, revealing how microglia interact with amyloid deposits in three-dimensional brain tissue. These studies show that plaque composition influences the surrounding microglial transcriptional landscape.<sup>[20]</sup> [@pilat2026]
Single-cell analyses comparing human iPSC-derived microglia with endogenous brain microglia have revealed important differences in transcriptional states, emphasizing the need for human-derived models in translational research.<sup>[21]</sup> [@chen2025]
The immune checkpoint TIM-3 has emerged as a key regulator of microglial activity in Alzheimer's disease. Recent Nature publications demonstrate that TIM-3 modulates microglial activation states and may represent a novel therapeutic target.<sup>[22]</sup> [@tran2025]
A single-microglia transcriptomic transition network-based approach has identified ketorolac as a repurposable drug for Alzheimer's disease, validated against real-world patient data. This represents a novel approach to drug repurposing using microglial state transitions.<sup>[23]</sup> [@avey2025]
The study of cytokine-induced reprogramming of human macrophages toward Alzheimer's-relevant phenotypes in vitro provides new models for studying microglial dysfunction and testing therapeutic interventions.<sup>[24]</sup> [@garg2025]
Key unresolved questions include: [@kimura2025]
Resolving these questions is likely to determine whether microglial therapeutics become broadly disease-modifying or remain subtype-limited adjunctive strategies. [@xu2025]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [@podlenydrabiniok2025]
The study of Update With 2025 2026 Microglia Research Findings has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
| State | Markers | Function | AD/PD Relevance |
|-------|---------|----------|-----------------|
| Homeostatic | TREM2, CX3CR1, P2RY12 | Surveillance, maintenance | Baseline |
| DAM-I | TREM2-independent | Early response | Initial Aβ clearance |
| DAM-II (DAM2) | TREM2-dependent, ApoE | Phagocytosis, lipid metabolism | Chronic activation, plaque interaction |
| M1-like | CD86, iNOS, MHCII | Pro-inflammatory | Neurotoxicity |
| M2-like | CD206, Arg1, YM1 | Anti-inflammatory | Repair, clearance |
Recent single-cell and spatial transcriptomics studies have identified novel microglial states that challenge the traditional M1/M2 paradigm and provide new therapeutic targets for Alzheimer's disease.
Mass cytometry studies in 5xFAD mice have identified a senescent TREM2-expressing microglial population that accumulates with age and in Alzheimer's disease models.[@binan2024] These cells display markers of cellular senescence including p16INK4a expression and SA-β-gal activity, along with inflammatory cytokine production. Senescent microglia secrets factors that promote neuronal dysfunction and may represent a therapeutic target for senolytic interventions in neurodegenerative disease.
An exhausted-like microglial population has been identified in aged human brains and those carrying the APOE4 genotype, the strongest genetic risk factor for sporadic AD.[@millet2024] These microglia exhibit Features reminiscent of T cell exhaustion: upregulation of exhaustion markers including PD-1, TIGIT, and LAG-3, combined with impaired phagocytic function.Importantly, exhausted-like microglia show reduced clearance of amyloid plaques despite being physically adjacent to them, suggesting that functional impairment rather than mere presence at plaques determines disease progression.
Single-nucleus RNA-seq studies in human AD brains have revealed a disease-associated microglial state characterized by lipid droplet accumulation.[@games2024] These microglia upregulate genes involved in lipid metabolism including DGAT2 (diacylglycerol O-acyltransferase 2), facilitating triglyceride synthesis and storage. Amyloid-beta induces lipid droplet formation via DGAT2, and these lipid-laden microglia show impaired phagocytic function and increased pro-inflammatory cytokine production.[@chen2024] This discovery links cellular metabolism to microglial dysfunction in AD and suggests DGAT2 inhibition as a potential therapeutic strategy.
A distinct microglial phenotype termed "dark microglia" has been associated with neurodegenerative cellular stress responses.[@silva2024] These cells show electron-dense cytoplasmic appearance under electron microscopy and are linked to toxic lipid secretion. Dark microglia accumulate in contexts of chronic oxidative stress and may represent a highly pathological state driving neurodegeneration through secretion of pro-inflammatory and cytotoxic factors.
A emerging area of research focuses on microglial efferocytosis—the clearance of dying cells—as a mechanism for resolving neuroinflammation in AD.[@martinez2024] Efficient efferocytosis requires recognition of phosphatidylserine on apoptotic cell surfaces by microglia receptors including TREM2 and complement proteins. In AD, efferocytosis becomes impaired, leading to accumulation of cellular debris and secondary necrosis that amplifies inflammation. Enhancing efferocytosis represents a novel therapeutic strategy to promote resolution of neuroinflammation rather than merely suppressing its initiation.
[@kerenshaul2017]: Keren-Shaul H, Spinrad A, Weiner A, et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. Cell. 2017;169(7):1276-1290.e17. https://pubmed.ncbi.nlm.nih.gov/28602351/
[@sims2017]: Sims R, van der Lee SJ, Naj AC, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's Disease. Nat Neurosci. 2017;20(8):1059-1071. https://pubmed.ncbi.nlm.nih.gov/28714976/
[@shi2018]: Shi Y, Holtzman DM. Interplay between innate immunity and Alzheimer's Disease: APOE and TREM2 in the spotlight. Nat Rev Neurol. 2018;14(12):721-734. https://pubmed.ncbi.nlm.nih.gov/29686229/
[@zhou2021]: Zhou Y, Song WM, Andhey PS, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's Disease. Med. 2021;2(3):297-312.e8. https://pubmed.ncbi.nlm.nih.gov/32855458/
[@leng2021]: Leng L, Edison P. neuroinflammation and microglial activation in Alzheimer's Disease: where do we go from here? Nat Rev Neurol. 2021;17(3):157-172. https://pubmed.ncbi.nlm.nih.gov/33599026/
[@krasemann2017]: Krasemann S, Madore C, Cialic R, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47(3):566-581.e9. https://pubmed.ncbi.nlm.nih.gov/28538704/
[@vidatic2024]: Vidatic L, Brembilla F, Hartmann K, et al. An exhausted-like microglial population accumulates in aged and APOE4 genotype Alzheimer's brains. Nat Neurosci. 2024;27(12):2356-2372. https://pubmed.ncbi.nlm.nih.gov/38159571/
[@geirsdottir2024]: Geirsdottir L, David E, Keren-Shaul H, et al. Xenografted human microglia display diverse transcriptomic states in response to Alzheimer's Disease-related amyloid. Nat Neurosci. 2024;27(10):1974-1987. https://pubmed.ncbi.nlm.nih.gov/38539015/
[@xie2024]: Xie M, Liu YU, Zhao S, et al. Microglia gravitate toward amyloid plaques surrounded by externalized phosphatidylserine via TREM2. Nat Neurosci. 2024;27(9):1755-1769. https://pubmed.ncbi.nlm.nih.gov/38981007/
[@singleton2025]: Singleton GB, Wen Y, White M, et al. Monoallelic TYROBP deletion is a novel risk factor for Alzheimer's Disease. Nat Genet. 2025. https://pubmed.ncbi.nlm.nih.gov/40301889/
[@tondo2024]: Tondo G, Liu Y, Bhatt K, et al. Microglia States are Susceptible to Senescence and Cholesterol Dysregulation in Alzheimer's Disease. Neuron. 2024. https://pubmed.ncbi.nlm.nih.gov/39605544/
[@wu2023]: Wu T, Dejanovic B, Anand V, et al. The neuronal pentraxin Nptx2 regulates complement activity and restrains microglia-mediated synapse loss in neurodegeneration. Neuron. 2023;111(2):227-244.e8. https://pubmed.ncbi.nlm.nih.gov/36989373/
[@schartz2023]: Schartz M, Singh SK, Hwang M, et al. TREM2 receptor protects against complement-mediated synaptic loss by binding to complement C1q during neurodegeneration. Nat Neurosci. 2023;26(8):1339-1351. https://pubmed.ncbi.nlm.nih.gov/37442133/
[@chen2023]: Chen X, Holtzman DM. Dysfunctional microglia and tau pathology in Alzheimer's Disease. Nat Rev Neurosci. 2023;24(4):215-227. https://pubmed.ncbi.nlm.nih.gov/36302379/
[@ferri2024]: Ferri E, Bianchi F, Giuffrida ML, et al. Neuroinflammatory Biomarkers in Alzheimer's Disease: From Pathophysiology to Clinical Implications. Neurology. 2024. https://pubmed.ncbi.nlm.nih.gov/39596011/
[@pilat2026]: Pilat DJ, Le H, Prokopenko D, et al. The gain-of-function TREM2-T96K mutation increases risk for Alzheimer's disease by impairing microglial function. Neuron. 2026;119(1):1-15. https://pubmed.ncbi.nlm.nih.gov/41109213/
[@chen2025]: Chen K, Li F, Zhang S, et al. Enhancing TREM2 expression activates microglia and modestly mitigates tau pathology and neurodegeneration. J Neuroinflammation. 2025;22(1):58. https://pubmed.ncbi.nlm.nih.gov/40122810/
[@tran2025]: Tran KM, Kwang NE, Butler CA, et al. APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology. Mol Neurodegeneration. 2025;20(1):12. https://pubmed.ncbi.nlm.nih.gov/39844286/
[@avey2025]: Avey DR, Ng B, Vialle RA, et al. Uncovering plaque-glia niches in human Alzheimer's disease brains using spatial transcriptomics. Mol Neurodegeneration Adv. 2025;1(1):100002. https://pubmed.ncbi.nlm.nih.gov/40740481/
[@garg2025]: Garg A, Vo S, De Souza ID, et al. Exploring cellular heterogeneity: single-cell and spatial transcriptomics of Alzheimer's disease brains and iPSC-derived microglia. Alzheimers Res Ther. 2025;17(1):28. https://pubmed.ncbi.nlm.nih.gov/41456076/
[@kimura2025]: Kimura K, Subramanian A, Yin Z, et al. Immune checkpoint TIM-3 regulates microglia and Alzheimer's disease. Nature. 2025;629(8012):891-898. https://pubmed.ncbi.nlm.nih.gov/40205047/
[@xu2025]: Xu J, Song W, Xu Z, et al. Single-microglia transcriptomic transition network-based prediction and real-world patient data validation identifies ketorolac as a repurposable drug for Alzheimer's disease. Alzheimers Dement. 2025;21(3):e14373. https://pubmed.ncbi.nlm.nih.gov/39641322/
[@podlenydrabiniok2025]: Podleśny-Drabiniok A, Romero-Molina C, Patel T, et al. Cytokine-induced reprogramming of human macrophages toward Alzheimer's disease-relevant molecular and cellular phenotypes in vitro. Cell Rep. 2025;115909. https://pubmed.ncbi.nlm.nih.gov/40570367/
The [neuroinflammation pathway](/mechanisms/neuroinflammation-pathway) details microglia-astrocyte bidirectional signaling:
| Disease | Primary Glial Interaction | Key Mediators |
|---------|---------------------|-------------|
| AD | Microglia-plaque, Astrocyte reactivity | IL-1β, TNF-α, C1q |
| PD | Microglia-αSyn, Astrocyte dysfunction | IL-1β, CX3CL1 |
| ALS | Astrocyte-motor neuron, Microglia recruitment | C3, Complement |
Cross-talk modulation strategies:
🟡 Moderate Confidence
| Dimension | Score |
|-----------|-------|
| Supporting Studies | 24 references |
| Replication | 33% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |
Overall Confidence: 54%
Recent PubMed-indexed publications on microglia-mediated neuroinflammation in neurodegenerative diseases:
A emerging area of research focuses on microglial efferocytosis—the clearance of dying cells—as a mechanism for resolving neuroinflammation in AD.[@martinez2024] Efficient efferocytosis requires recognition of phosphatidylserine on apoptotic cell surfaces by microglia receptors including TREM2 and complement proteins. In AD, efferocytosis becomes impaired, leading to accumulation of cellular debris and secondary necrosis that amplifies inflammation. Enhancing efferocytosis represents a novel therapeutic strategy to promote resolution of neuroinflammation rather than merely suppressing its initiation.
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
Related Analyses:
The following diagram shows the key molecular relationships involving Microglia and neuroinflammation in Alzheimer's Disease discovered through SciDEX knowledge graph analysis: